FDA OK’s U.S. Trial of Pulmonx Emphysema Therapy

In short

Interventional Pulmonology company Pulmonx, has announced that the U.S. FDA has approved its request for an Investigational Device Exemption (IDE) to commence a multi-centre pivotal clinical trial which the company hopes will support a subsequent premarket approval application (PMA) for the Zephyr® Endobronchial Valve (EBV). This new trial will incorporate the use of the Pulmonx Chartis® System to plan valve treatment.

Background

We’ve covered Pulmonx’s European-based progress a few times before, most recently with the announcement of clinical results in May of this year.

The Zephyr® Endobronchial Valve is a minimally invasive device intended to treat patients with emphysema by reducing volume in the diseased portion of the lungs, thereby improving the ability of the healthier portions of the lungs to function. This is expected to relieve the patient’s symptoms, allowing them to increase their activity levels, while promoting better overall health. The company says the procedure is relatively easy for physicians to perform, and unlike other presently available Lung Volume Reduction therapies which are irreversible, the Zephyr® implant can later be removed if necessary.

Chartis® is a first of its kind pulmonary assessment system that provides critical real time information to improve the planning of EBV treatment.

The Zephyr® EBV received the CE Mark in 2003, since which time the company estimates that it has been used to treat approximately 4,000 patients, over 40 percent of whom have been treated in the last 12 months. A recently published multi-centre European study reported that, using Chartis®, in those patients who were predicted to respond, there was a statistically significant improvement in target lobe volume reduction and FEV1 at thirty days compared to those who were predicted not to respond. These patients showed a mean percentage increase in FEV1 of 16% (a standard pulmonary function test in which a 15% improvement is commonly considered to be clinically significant) and a mean improvement in quality of life as scored by the SGRQ (St. George’s Respiratory Questionnaire, a clinically validated quality of life measure) of 10 points, which is two and one half times the level considered clinically significant.

Clinician comments

“Emphysema is a terribly debilitating disease that affects the lives of literally millions of Americans,” said Armin Ernst, MD, MHCM, FCCP; Chief, Pulmonary, Critical Care and Sleep Medicine at St. Elizabeth’s Medical Center and Professor of Medicine at Tufts University School of Medicine in Boston, who serves as a co-principal investigator for the Zephyr® trial. “There is a large, unmet need for non-invasive treatment of emphysema designed for patients who currently have very few options in the U.S.”

On the Chartis system, Gerard J. Criner, MD, Professor and Chairman Department of Medicine, Chief Division of Pulmonary & Critical Care Medicine, Temple University School of Medicine, also a co-principal investigator for the Zephyr® trial, said; “A recently published trial in Europe has shown that it is possible to use the new Chartis® technology to plan EBV treatments with a high level of accuracy, which provides the opportunity to obtain with better consistency greater clinical responses in lung function, exercise tolerance, and quality of life measures than was seen in the overall results from the earlier VENT study1. “If we can confirm these benefits in this pivotal trial, Pulmonx’s Zephyr® EBV therapy could represent an important breakthrough in the treatment of emphysema in the US.”

“We’ve had excellent success with EBV therapy in our practice and with the introduction of the Chartis® System it is rapidly becoming a standard of care here in Europe,” said Professor Felix Herth, MD, PhD, FCCP, Chairman and Head of Pneumology and Respiratory Care at Thoraxklinik, University of Heidelberg, who will serve as an advisor for the U.S. study.

Regulatory status

The Zephyr® EBV is an investigational device in the United States. Limited by U.S. law to investigational use.

References

1Herth FJ, Eberhardt R, Gompelmann D, Ficker JH, Wagner M, Ek L, Slebos DJ. Radiological and Clinical Outcomes of Using Chartis® to Plan Endobronchial Valve Treatment. Published on May 3, 2012 as doi: 10.1183/09031936.00015312 ERJ Express

Source: Pulmonx